What is the initial dosage of Eliquis (apixaban) for left ventricular thrombus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The initial dosage of Eliquis (apixaban) for left ventricular thrombus is not explicitly stated in the provided evidence, but based on the available data for VTE treatment, apixaban is typically initiated at 10 mg orally twice daily for the first 7 days of therapy, followed by 5 mg orally twice daily 1. However, it's essential to note that this dosage is recommended for venous thromboembolism (VTE) treatment, and left ventricular thrombus treatment may require a different approach.

  • The dosage of 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily, is based on the anticoagulation dosing table for VTE treatment 1.
  • In clinical practice, the dosage of apixaban for left ventricular thrombus may be adjusted based on patient-specific factors, such as age, weight, and renal function.
  • It's crucial to monitor patients for bleeding complications and adjust the treatment plan accordingly.
  • The treatment duration for left ventricular thrombus typically ranges from 3-6 months, with follow-up imaging to confirm thrombus resolution before considering discontinuation.
  • Apixaban's predictable pharmacokinetics, fewer drug interactions, and no need for routine monitoring make it an attractive alternative to traditional anticoagulants like warfarin for left ventricular thrombus treatment.

From the Research

Eliquis (Apixaban) Initial Dosage for Left Ventricular Thrombus

The initial dosage of Eliquis (apixaban) for left ventricular thrombus is not explicitly stated in the provided studies. However, the following information can be gathered:

  • A study published in 2021 compared warfarin and direct oral anticoagulants (DOACs) for the treatment of left ventricular thrombus, but it did not specify the initial dosage of apixaban 2.
  • Another study published in 2022 compared apixaban and warfarin in patients with left ventricular thrombus, but it only mentioned that apixaban was administered at a dose of 5 mg twice daily, without specifying if this was the initial dosage 3.
  • A study published in 2021 assessed the effects of different oral anticoagulant regimens on pump thrombosis in a HeartWare ventricular assist device, and it mentioned that apixaban was used at a low dose (equivalent to 2.5 mg twice daily) and a high dose (equivalent to 5 mg twice daily), but it did not provide information on the initial dosage for left ventricular thrombus 4.

Key Points

  • The initial dosage of apixaban for left ventricular thrombus is not clearly stated in the provided studies.
  • Apixaban was used at a dose of 5 mg twice daily in a study comparing it to warfarin for the treatment of left ventricular thrombus 3.
  • Different dosages of apixaban (2.5 mg twice daily and 5 mg twice daily) were used in a study assessing its effects on pump thrombosis in a HeartWare ventricular assist device 4.

Dosage Information

  • The dosage of apixaban used in the studies varied, but the most common dosage mentioned was 5 mg twice daily 3, 4.
  • The low dose of apixaban (2.5 mg twice daily) was also used in one of the studies 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.